Search
Search
Close this search box.

A complete view of trends following the introduction of cannabis 2.0 products.

The CCSI was assessed at C$5.09 per gram this week, down from last week’s C$5.14 per gram. This week’s price equates to US$1,807 per pound at the current exchange rate.

Each week, Business of Cannabis delivers a series of insights from our partners at Cannabis Benchmarks®.

This week we continue to examine data published in the Ontario Cannabis Store’s (OCS) quarterly Cannabis Insights report, which covers the period from October through December 2021. This report focuses on the proportion of sales dedicated to cannabis 1.0 and 2.0 products in Ontario. As a reminder, cannabis 1.0 refers to the legalization of combustible cannabis flower, cannabis oils, and cannabis seeds in October 2018.  A year later cannabis 2.0 began, making available to consumers derivative products such as vapes, edibles, beverages, concentrates, and topicals. The data aggregated in today’s CCSI report reviews a series of OCS quarterly reports to compile a complete view of trends following the introduction of cannabis 2.0 products.


Now that we have over two years of data, we can see cannabis 2.0 products starting to make up a notable share of sales. Total cannabis sales in Ontario have been accelerating with the rapid build-out of brick-and-mortar stores. From December 2020 to December 2021, cannabis 2.0 product sales have jumped from making up 26% of total sales to over 30%.


Diving deeper into the cannabis sales mix, we see that most consumers prefer the traditional smokeable or inhalable products (dry flower or vapes, respectively), with all other derivative products making up very small proportions of total sales. That said, modest increases in spending on edibles and concentrates can be seen in the chart below, which compares the sales mix from the end of 2020 and 2021.

Source: Canada Cannabis Spot IndexCannabis Benchmarks

See previous weekly updates from Cannabis Benchmarks:



⏰ Pre-order discount ends Jan 15
-- Days
-- Hours
-- Mins
Data packs delivered January 2026
🔬 New Report Due January 2026

Global Medical Cannabis Market Review 2026

A comprehensive analysis of the international medical cannabis supply chain — examining country-specific data on exports, imports, market size, domestic production, and distribution landscapes. Understand the driving forces behind global supply dynamics, the impact of telemedicine on patient access, and regulatory changes shaping the market.

What's covered

  • 📊 Global supply chain overview — understand export/import dynamics and domestic production capabilities
  • 🌍 8 export country snapshots — Canada, Portugal, Denmark, North Macedonia, Spain, Australia, Czech Republic, South Africa
  • 👥 6 patient market snapshots — Australia, Germany, UK, Poland, Brazil, France
  • 🔮 Key themes — Canada's global impact, telemedicine growth, new market openings, quota changes
Export Markets
🇨🇦 Canada 🇵🇹 Portugal 🇩🇰 Denmark 🇲🇰 N. Macedonia 🇪🇸 Spain 🇦🇺 Australia 🇨🇿 Czechia 🇿🇦 South Africa
Patient Markets
🇦🇺 Australia 🇩🇪 Germany 🇬🇧 UK 🇵🇱 Poland 🇧🇷 Brazil 🇫🇷 France
100% free • No credit card required
As trusted by
DIAGEO KPMG Coca-Cola BARCLAYS BNP PARIBAS AB InBev NOVARTIS Johnson & Johnson PEPSICO AXA POLITICO Bloomberg amazon CNN Business
Part of our annual market review series GDPR compliant

Related Posts

Related Posts

CONNECT

Related Posts

Related Posts

Recent Posts

Related Posts

Subscribe to our mailing list to receives daily updates!

We won’t spam you

Categories

Browse by Tags

CATEGORIES

EDITION

BUSINESS OF CANNABIS

© 2023 Prohibition Holdings Ltd. All Rights Reserved.

EDITION

Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?